Global Mpox Trends
Key figures
This report provides a comprehensive summary of data from the global mpox surveillance started by WHO in 2022, and strengthened during the ongoing public health emergency of international concern (PHEIC). For information on specific topics:
| Topic | Relevant sections |
|---|---|
| Global distribution of clade Ib MPXV | Section 2.2 |
| Clade II, Ia, and Ib MPXV in Africa | Section 3 |
| Clade Ia and Ib MPXV in the Democratic Republic of the Congo | Section 4 |
| Global epidemiology (largely clade IIb MPXV) | Section 5 |
For further information on the epidemiological situation in Africa, see Section 3
For further information on the epidemiological situation in Africa, see Section 3.
Values shown here are subject to case definitions used by their respective countries. For more information see Section 3.5.
For further information on the epidemiological situation in Africa, see Section 3
For further information on the distribution of MPXV clades see Section 2
Data as updated weekly; from 01 January 2024 to 04 May 2025. Note that data shown here includes laboratory confirmed cases only. The most recent weeks presented in the epidemic curves should be interpreted with caution, as there are delays associated with reporting.
In the Democratic Republic of the Congo, a small number of cases are not represented on epidemic curves due to missing dates.
| Summary of confirmed mpox cases in key countries | ||||||||
|---|---|---|---|---|---|---|---|---|
| As of 04 May 2025 | ||||||||
| Country | Total cases in 2024 | Total deaths in 2024 | Total cases in 2025 | Total deaths in 2025 | Cases in the past six weeks1 | Deaths in the past six weeks1 | Clades detected in country | Date of last reported case |
| Democratic Republic of the Congo | 14 238 | 27 | 7411 | 22 | 1610 | 2 | Clades Ia and Ib | 27 Apr 2025 |
| Uganda | 1352 | 13 | 4590 | 28 | 1307 | 4 | Clade Ib | 4 May 2025 |
| Sierra Leone | 0 | 0 | 1387 | 10 | 1275 | 8 | Clade II (a and/or b) | 4 May 2025 |
| Burundi | 2946 | 1 | 937 | 0 | 185 | 0 | Clade Ib | 4 May 2025 |
| Kenya | 31 | 1 | 66 | 1 | 36 | 1 | Clade Ib | 4 May 2025 |
| Rwanda | 82 | 0 | 32 | 0 | 1 | 0 | Clade Ib | 30 Mar 2025 |
| 1 From 24 Mar 2025 to 04 May 2025 | ||||||||
Data as updated weekly; from 01 January 2022 to 04 May 2025. Note that data shown here refers to laboratory confirmed cases only, and are collected from the continent of Africa, across the WHO African and Eastern Mediterranean regions.
Total lab confirmed cases in week 18 2025
797
Total lab confirmed deaths in week 18 2025
5
Countries reporting cases in week 18 2025
6
Total lab confirmed cases in 2025
14 758
Total lab confirmed deaths in 2025
67
Countries reporting cases in 2025
18
Total lab confirmed cases since 2022
36 341
Total lab confirmed deaths since 2022
141
Countries reporting cases since 2022
28
Data as updated monthly; from 01 January 2022 to 31 March 2025
Total lab confirmed cases in March 2025
4259
Total lab confirmed deaths in March 2025
25
Countries reporting cases in March 2025
50
Total lab confirmed cases in 2025
12 531
Total lab confirmed deaths in 2025
62
Countries reporting cases in 2025
66
Total lab confirmed cases since 2022
138 029
Total lab confirmed deaths since 2022
317
Countries reporting cases since 2022
132
1 Overview
This report provides an overview of the mpox1 epidemiological situation, based on global surveillance data reported to WHO from 01 January 2022, initiated due to the unprecedented human-to-human spread of monkeypox virus (MPXV) globally occurring in the same year.
1 On of 28 November 2022, WHO recommended using the name mpox as a new name for monkeypox. The words were used synonymously for one year as the term monkeypox was phased out. The virus causing mpox is named monkeypox virus (MPXV).
2 A summary of the geographic distribution of MPXV clades is included in Section 2.
Distinct MPXV clades and subclades are impacting diverse populations in different geographical regions, each exhibiting varied transmission dynamics2. On 14 August 2024, under the provisions of the International Health Regulations (2005), the WHO Director-General determined that the upsurge of mpox in the Democratic Republic of the Congo (DRC) and in a growing number of countries in Africa constitutes a public health emergency of international concern (PHEIC). Its spread presents a public health risk to other Member States and requires a coordinated international response.
WHO conducted the latest global mpox rapid risk assessment in February 2025. Based on the available information, the risk is assessed as follows:
| MPXV clade | Areas/populations affected | Overall risk level3 |
|---|---|---|
| Clade Ib | Predominantly affecting non-endemic areas for mpox in the Democratic Republic of the Congo and neighbouring countries | High |
| Clade Ia | Primarily affecting endemic areas for mpox within the Democratic Republic of the Congo | Moderate4 |
| Clade II | Observed in Nigeria and endemic countries in West and Central Africa | Moderate |
| Clade IIb | Associated with the global mpox epidemic first documented in 2022 | Moderate |
3 Possible risk levels are Low, Medium, High, and Very High
4 The situation in Kinshasa warrants specific focus and is linked to a higher risk of spread.
Please note that regardless of geographic area, epidemiological context, biological sex, gender identity or sexual behaviour, individual-level risk is largely dependent on individual factors such as exposure risk and immune status.
This report mainly focuses on confirmed cases and deaths as defined by WHO’s working case definition published in the surveillance, case investigation and contact tracing for mpox interim guidance. For countries with suboptimal testing rate, such as the Democratic Republic of the Congo, laboratory confirmed and suspected cases are both shown where possible to better describe the national epidemiological situation. Note that countries5 may use slightly different case definitions from those proposed by WHO, nevertheless all confirmed mpox cases need to have a positive laboratory test result.
5 Throughout this document, any use of the word country should be considered shorthand for a country, area, or territory
2 Summary of MPXV clades
Phylogenetic tree of all MPXV clades
Based on phylogenetic analysis, MPXV6 is divided into two major clades: clade I (one, formerly Congo Basin clade) and clade II (two, formerly West Africa clade). Each of these clades is further subdivided into two subclades: clade Ia and clade Ib within clade I; clade IIa and clade IIb within clade II.
6 MPXV genetic sequences are routinely shared within NCBI GenBank and GISAID databases.
Clade Ia MPXV circulates within multiple countries in Central Africa and is associated with regular spillover from animal reservoirs with some onward human-to-human transmission. Mixing of virus sequences from these countries within the clade Ia phylogenetic tree shows cross-border movement of clade Ia viruses.
Clade Ib MPXV recently emerged in the eastern part of the Democratic Republic of the Congo7 and is undergoing sustained human-to-human transmission.
Clade IIa MPXV has historically rarely been isolated and documented in humans with most available genetic sequences coming from animal species, and more recent transmission in several West African countries.
Clade IIb MPXV, first detected in Nigeria, has undergone extended sustained circulation within humans since at least 2016 and has caused a large ongoing outbreak from 2022 to present. During the global outbreak, it has largely been associated with transmission among men who have sex with men. This outbreak reached its highest peak in August 2022, and continues to circulate at low levels in several countries.
7 More information on the geographical distribution of clades Ia and Ib MPXV can be seen in Section 4
2.1 Imported cases and clusters of clade I MPXV
The following table summarizes the available information on reported imported cases, and where applicable, onward cases of clade I MPXV. This table includes some imported cases from countries which have gone on to report community transmission8.
8 This table is available for download in Section 7
2.2 Geographical spread of clade Ib MPXV
This section gives an overview of clade Ib MPXV distribution in affected countries, as well as imported travel related cases, in line with the recommendations of the International Health Regulations (IHR, 2005) Emergency Committee on the upsurge of mpox in 2024.
Based on the presence of clade Ib mpox cases reported in the past six weeks, a country is classified as having:
Community transmission, if:
At least one reported case has no epidemiological link to travel or contact with a traveler from a country with known mpox transmission. This classification applies regardless of the total number of cases reported.
Cases linked to travel, if all reported cases are either:
Individuals who traveled to a country with known mpox transmission, were likely exposed there, and were diagnosed upon return or arrival.
OR
Individuals who did not travel themselves but had direct contact with someone who traveled to an affected country where the exposure occurred.
Unknown:
Insufficient information is available to determine if cases are due to community transmission or linked to travel.
Based on the presence of clade Ib mpox cases reported in the past six weeks, a country is classified as having:
Community transmission, if:
At least one reported case has no epidemiological link to travel or contact with a traveler from a country with known mpox transmission. This classification applies regardless of the total number of cases reported.
Cases linked to travel, if all reported cases are either:
Individuals who traveled to a country with known mpox transmission, were likely exposed there, and were diagnosed upon return or arrival.
OR
Individuals who did not travel themselves but had direct contact with someone who traveled to an affected country where the exposure occurred.
Previously reporting cases, if:
No new clade Ib MPXV cases have been reported for a period of more than six consecutive weeks since the last case, regardless of the previous transmission classification. Transmission is in control phase.
Unknown:
Insufficient information is available to determine if cases are due to community transmission or linked to travel.
The following table includes countries reporting clade Ib MPXV in the past six weeks, and aims to classify their transmission dynamics into two ordinal categories9. If countries have not reported cases in the past six weeks, they are not considered to have active clade Ib transmission.
9 Transmission status is based on information reported to WHO, and does not account for instances where transmission may not be detected.
| Clade Ib MPXV transmission classifications | ||||
|---|---|---|---|---|
| Country1 | Cases since Jan 2024 | Cases in past 6 weeks | Transmission status2 | Additional notes |
| Democratic Republic of the Congo | 3 21 649 | 3 1610 | Community transmission | - |
| Uganda | 5942 | 1307 | Community transmission | - |
| Burundi | 3883 | 185 | Community transmission | - |
| Rwanda | 114 | 1 | Community transmission | - |
| Kenya | 97 | 36 | Community transmission | - |
| Zambia | 64 | 37 | Community transmission | - |
| Congo | 59 | 9 | Community transmission | - |
| United Republic of Tanzania | 41 | 14 | Community transmission | - |
| South Sudan | 11 | 4 | Community transmission | - |
| Malawi | 6 | 6 | Community transmission | - |
| The United Kingdom | 12 | 1 | Cases linked to travel | - |
| Germany | 10 | 2 | Cases linked to travel | - |
| Thailand | 5 | 1 | Cases linked to travel | - |
| France | 3 | 1 | Cases linked to travel | - |
| United Arab Emirates | 2 | 1 | Cases linked to travel | - |
| Switzerland | 1 | 1 | Cases linked to travel | - |
| Note: Imported cases are updated as of 08 May 2025 whereas case counts for countries classified as community transmission are updated as of 04 May 2025. | ||||
| 1 For countries classified as having cases linked to travel, only cases of mpox due to clade Ib MPXV are included. Cases in these countries for which clade and subclade classification is not determined or pending are not included. Note that multiple exported cases have been detected in travellers returning from United Arab Emirates, indicating likely community transmission in-country. | ||||
| 2 Countries with cases linked to travel also include instances where one to two generations of onward transmission have been reported, and linked to index cases. | ||||
| 3 Cases reported in Congo and the Democratic Republic of the Congo are known to be a mix of clade Ia and clade Ib MPXV. | ||||
| Clade Ib MPXV cases by country | |||
|---|---|---|---|
| Country | WHO region | Cases since Jan 2024 | Cases in past 6 weeks |
| Democratic Republic of the Congo | African Region | 1 21 649 | 1 1610 |
| Uganda | African Region | 5942 | 1307 |
| Burundi | African Region | 3883 | 185 |
| Rwanda | African Region | 114 | 1 |
| Kenya | African Region | 97 | 36 |
| Zambia | African Region | 64 | 37 |
| Congo | African Region | 59 | 9 |
| United Republic of Tanzania | African Region | 41 | 14 |
| The United Kingdom | European Region | 12 | 1 |
| South Sudan | African Region | 11 | 4 |
| Germany | European Region | 10 | 2 |
| India | South-East Asia Region | 10 | 0 |
| China | Western Pacific Region | 7 | 0 |
| South Africa | African Region | 6 | 0 |
| Malawi | African Region | 6 | 6 |
| Belgium | European Region | 5 | 0 |
| Qatar | Eastern Mediterranean Region | 5 | 0 |
| Thailand | South-East Asia Region | 5 | 1 |
| United States of America | Region of the Americas | 4 | 0 |
| France | European Region | 3 | 1 |
| Angola | African Region | 2 | 0 |
| United Arab Emirates | Eastern Mediterranean Region | 2 | 1 |
| Canada | Region of the Americas | 1 | 0 |
| Oman | Eastern Mediterranean Region | 1 | 0 |
| Pakistan | Eastern Mediterranean Region | 1 | 0 |
| Sweden | European Region | 1 | 0 |
| Zimbabwe | African Region | 1 | 0 |
| Brazil | Region of the Americas | 1 | 0 |
| Switzerland | European Region | 1 | 1 |
| Note: Imported cases are updated as of 08 May 2025 whereas case counts for countries classified as community transmission are updated as of 04 May 2025. | |||
| 1 Cases reported in Congo and the Democratic Republic of the Congo are known to be a mix of clade Ia and clade Ib MPXV. | |||
The following map shows countries reporting clade Ib MPXV in the past six weeks, and aims to classify their transmission dynamics into two ordinal categories. If countries have not reported cases in the past six weeks, they are not considered to have active clade Ib transmission.
Clade Ib MPXV has been reported in the following countries. The timeline below shows the date of report to WHO, place of travel, and number of onward cases reported.
Cases which led to onward cases are shown in red, while cases with no onward transmission are shown in blue.
2.3 Geographical spread of clade Ia MPXV
This section gives an overview of clade Ia MPXV distribution in affected countries, as well as imported travel related cases. MPXV clade Ia is endemic in several countries in Central Africa, and is associated with regular spillover from animal reservoirs. However, like clade Ib, some sublineages of clade Ia have recently been linked to sustained human to human transmission.
Endemic:
Countries with a historical reporting of clade Ia MPXV cases, likely due to zoonotic spillover events from local animal fauna
Community transmission:
Non-endemic countries reporting ongoing local transmission, including unlinked cases affecting population groups throughout the community
Cases linked to travel:
Countries reporting cases likely infected in other countries, including instances where one to two generations of onward transmission have been reported in country, and linked to index cases.
Unknown:
Insufficient information is available to determine if cases are due to community transmission or linked to travel.
The following table includes countries reporting clade Ia MPXV, and aims to classify their transmission dynamics into three ordinal categories.
| Transmission status by country: clade Ia MPXV | ||
|---|---|---|
| 1 January 2022 to 04 May 2025 | ||
| Country | WHO Region | Transmission status1 |
| Cameroon | African Region | Endemic |
| Central African Republic | African Region | Endemic |
| Congo | African Region | Endemic |
| Democratic Republic of the Congo | African Region | Endemic |
| Sudan | Eastern Mediterranean Region | Endemic |
| China | Western Pacific Region | Cases linked to travel |
| Ireland | European Region | Cases linked to travel |
| Note: Imported cases are updated as of 08 May 2025 whereas case counts for countries classified as community transmission are updated as of 04 May 2025. | ||
| 1 Countries with cases linked to travel also include instances where one to two generations of onward transmission have been reported, and linked to index cases. | ||
3 Situation in Africa
This section is jointly authored by the WHO Regional Office for Africa, the WHO Regional Office for the Eastern Mediterranean10 and WHO Headquarters.
10 On the African continent there are 47 Member States in the WHO African Region and seven in the WHO Eastern Mediterranean Region.
Since 1 January 2022, cases of mpox have been reported to WHO from 28 Member States across Africa. As of 04 May 2025 , a total of 36 341 laboratory confirmed cases, including 141 deaths, have been reported to WHO.
In the past twelve months, as of 04 May 2025, 24 countries have reported 29 392 confirmed cases, including 112 deaths. The three countries with the majority of the cases in the last 12 months are Democratic Republic of the Congo, (n = 17 171), Uganda, (n = 5942), and Burundi, (n = 3883).
In the Democratic Republic of the Congo a significant number of suspected mpox cases, that are clinically compatible with mpox remain untested due to limited diagnostic capacity and thus never get confirmed11. Moreover, not all countries have robust surveillance systems12 for mpox, meaning reported case counts are likely underestimating the extent of community transmission.
11 This indicator should be interpreted with caution, as suspected mpox cases are recorded according to varying national case definitions.
12 Surveillance may also be affected by differences in case definitions across countries. These can be viewed in Section 3.5.
3.1 Outbreak status and MPXV clade distribution
The distribution of clades reported in Africa, and the outbreak status of countries on the continent is shown in the maps below. The distribution of reported mpox clades in Africa is also shown below.
Maps can be clicked to view on a larger scale.
Outbreak status of countries is shown below13.
13 Countries with active mpox transmission are classified as those that have reported cases to WHO within the past 42 days. If a country does not share information on mpox cases or provide regular zero-case reporting to WHO or any other open-access resources, its outbreak status may not accurately reflect its current situation on the map.
Clade distribution is shown below14. Note that subnational distributions of MPXV clades are not captured in this figure.
14 In many cases, sequencing may not capture all circulating clades, leading to under-representation of where clades are circulating.
3.2 Epidemic curves
Epidemic curve shown by week for cases reported up to 04 May 2025. The most recent weeks presented in the epidemic curves should be interpreted with caution, as there are delays associated with reporting.
3.2.1 Confirmed cases
The following epidemic curve shows the number of confirmed cases by week for countries in Africa. Use the dropdowns to select the time range and countries to display.
In the Democratic Republic of the Congo, a small number of cases are not represented on epidemic curves due to missing dates.
3.2.2 All cases in the Democratic Republic of the Congo
All cases, including suspected and lab confirmed cases are shown from 2024. We exceptionally highlight the Democratic Republic of the Congo due to the testing shortage in country, where only a third of cases in 2024 were tested.
3.3 Maps
Maps can be clicked to view on a larger scale. Note that data are only shown for Africa - data from elsewhere are reflected in the global sections of the report.
3.4 Data by country
Data by country is available in table format here.
3.4.1 Laboratory confirmed cases
3.5 Case definitions
This section includes the national case definition used in African countries in order to provide more context for the interpretation of data, especially of suspected cases.
Case definitions for suspected cases are shown for the following countries below:
Suspected case:
A person with sudden onset of high fever followed by a vesiculopustular rash predominantly on the face and present on the palms of the hands and soles of the feet; OR presence of at least 5 smallpox-like scars,
OR
Any person with fever > 38.3 °C (101 F), severe headache, lymphadenopathy, back pain, myalgia, and severe weakness, followed 1-3 days later by a progressive rash that often begins on the face (more dense) and then spreads elsewhere on the body, including the soles of the feet and palms of the hands.
Confirmed case:
Any case for which the clinical and epidemiological diagnosis of mpox has been laboratory confirmed.
4 Situation in the DRC
Here, we exceptionally present an overview of the ongoing situation in the Democratic Republic of the Congo, in agreement with the national Ministry of Public Health.
The current spread of mpox in the Democratic Republic of the Congo is attributed to two increasingly interspersed outbreaks:
The spread of clade Ia MPXV, largely in endemic provinces of the country15, and
The spread of clade Ib MPXV, which emerged in 2023 in the South Kivu province16.
15 Endemic provinces are: Equateur, Sankuru, Tshuapa, Tshopo, Nord Ubangi, Bas Uele, Sud-Ubangi, Mongala, Kwilu, Maindombe, and Maniema, where in the DRC, an endemic area is considered to be one which has reported mpox cases for at least five consecutive years.
16 Cases of clade Ib MPXV have been detected in Haut Katanga, Kasai, Kinshasa, Kongo Central, Lomami, Maindombe, Nord Kivu, Sud-Kivu, Tanganyika, and Tshopo.
Clade Ia MPXV is associated with zoonotic spillover from animal reservoirs followed by some human-to-human transmission. Emerging evidence shows that human-to-human transmission has been sustained in Kinshasa since the second half of 2024. In contrast, epidemiological and sequencing information show that clade Ib MPXV is associated predominantly with human-to-human transmission.
In this section, clade distribution across provinces is based on sequencing data provided by the Democratic Republic of the Congo National Institute of Biomedical Research (INRB). Geographical representation may be incomplete, and the actual clade distribution could be broader and more nuanced than currently presented.
The report presents trends based on three key data sources:
| Source | Description | Usage |
|---|---|---|
| Syndromic mpox surveillance system | Data on suspected mpox cases and deaths collected via the Integrated Disease Surveillance database (IDS). Cases that are tested and are negative are not retrospectively removed once reported. Data delay of 1-2 weeks. | Overall case and death numbers, and trends in cases. |
| Laboratory data | Mpox suspected cases that are sampled and tested. Data delay varies between different provinces and the distance from the reference laboratory. | Confirmed case numbers and trends in confirmed cases. |
| Case-based epidemiological data | Detailed information about all investigated cases, including case classification based on sampling and testing. Completeness and delays vary between different provinces. | Demographic characteristics of cases |
| Sequencing metadata | Basic case-based information about confirmed cases that are sequenced. | Information on the clade distribution of MPXV in the country |
All surveillance data are subject to reporting delays, and data cleaning is ongoing. As a result, sub-national case counts in this section may lag behind those reported at the national level. Mpox surveillance coverage and completeness in the Democratic Republic of the Congo varies over geographic space and time, and in some cases data sources may not be fully harmonised.
4.1 Situation summary
The map is generated using sequences that are publicly available in the INRB, GISAID and Genbank databases. MPXV sequences from Democratic Republic of the Congo are shown from October 2023, with the latest sequence here sampled on 03 March 2025.
Trends shown for the 16 provinces reporting the highest numbers in the past six weeks. Data shown for all cases, via syndromic surveillance system.
4.2 Genomic surveillance
In this subsection, we present visualizations of sequences that are publicly available in the INRB, GISAID and Genbank databases. The latest MPXV sequence from the Democratic Republic of the Congo was sampled on 03 March 2025.
When interpreting these data, it is important to note that the availability of sequences is not uniform across time and space, and that the distribution of sequences may not be representative of the true distribution of clades in the country.
Samples associated with clade Ib MPXV were first collected in late 2023 - the designation of this lineage in 2024 retrospectively classified all previously identified sequences as clade Ia MPXV (previously they would be considered clade I). Therefore, all sequences identified before 2023 are retrospectively attributable to ancestral clade Ia MPXV.
The map below shows the distribution of MPXV sequences from the Democratic Republic of the Congo from 2023. The color of each province represents the proportion of sequences that are clade Ib MPXV17.
17 Sequences are obtained from metadata shared by the Democratic Republic of the Congo National Institute of Biomedical Research (INRB), and from publicly available sequences on Genbank and GISAID.
4.3 Laboratory testing
This section presents indicators related to mpox testing in the Democratic Republic of the Congo, including the proportion of suspected cases sampled and test positivity among sampled cases over time. Tests are performed by a laboratory network throughout the country using conventional PCR testing and GeneXpert PCR.
Throughout this section, sampling percentages are calculated as the number of cases sampled (based on national laboratory line list data) divided by the number of cases reported through the syndromic surveillance system for the geographic unit. Please note, since this calculation draws from two separate data sources, date misalignments may lead to discrepancies.
Test positivity is calculated as the number of positive PCR samples out of the total tested for each geographic unit.
| Laboratory testing by geographic area | ||
|---|---|---|
| from 01 Jan 2024 to 27 Apr 2025 | ||
| % suspected cases tested | % tested cases positive | |
| Kinshasa | - | 43.2% |
| Sud-Kivu | 43.5% | 70.5% |
| Nord Kivu | - | 30.2% |
| Endemic provinces | 21.1% | 56.8% |
4.3.1 National level
Weekly percentages of suspected cases for whom a sample was collected and weekly percentage of confirmed cases through laboratory testing. Sampling and confirmation percentages follow the same calculation methods described above. Positivity rates are based solely on national laboratory line list data. Wider confidence intervals indicate smaller sample sizes or more variable positivity18 19.
18 Confidence intervals are calculated via the binomial distribution.
19 The decrease in the proportion of cases sampled after the PHEIC declaration in August 2024 is linked to the increase in case detection. Similarly, the decrease in the proportion of cases positive is influenced by the increase in testing after August 2024.
4.3.2 By province
Sampling percentages are not shown for Kinshasa, as all cases are sampled. Nord Kivu is excluded due to differences in syndromic case reporting over time.
Variations in positivity rates may reflect differences in disease incidence as well as sampling and testing capacity and strategy over time20 21.
20 Confidence intervals are calculated via the binomial distribution.
21 The decrease in the proportion of cases sampled after the PHEIC declaration in August 2024 is linked to the increase in case detection. Similarly, the decrease in the proportion of cases positive is influenced by the increase in testing after August 2024.
4.3.3 By province and age group
Weekly percentages of suspected cases for whom a sample was collected and confirmed through laboratory testing by age across four geographic areas in the Democratic Republic of the Congo. Sampling percentages are not shown for Kinshasa, as all cases are sampled. Nord Kivu is excluded due to differences in syndromic case reporting over time.
| % suspected cases sampled and %tested cases positive by age and geographic area | ||||||
|---|---|---|---|---|---|---|
| from 01 Jan 2024 to 27 Apr 2025 | ||||||
% Suspected Cases Tested
|
% Tested Cases Positive
|
|||||
| 0-4 yrs | 5–14 yrs | 15+ yrs | 0–4 yrs | 5–14 yrs | 15+ yrs | |
| Kinshasa | - | - | - | 45.7% | 49.7% | 76.0% |
| Sud-Kivu | 15.4% | 37.1% | 39.0% | 62.1% | 55.4% | 72.3% |
| Nord Kivu | - | - | - | 23.3% | 22.7% | 37.9% |
| Endemic provinces | 9.2% | 21.7% | 23.6% | 50.7% | 52.7% | 55.9% |
4.4 Data tables
Total cases and death columns reflect data for 2024 and 2025.
This table is generated from multple data sources. In some cases where delays in reporting do not match, the percentage of cases tested may be higher than the number of total cases.
The following table is shown for the health zones with the highest numbers of recorded cases in the past six weeks.
4.5 Maps
Distribution of cases and deaths can be explored in the Democratic Republic of the Congo at the provincial and health zone levels22. The maps are interactive and can be explored by clicking on the layers in the legend to show or hide the different layers. Note that the legend scale varies across layers.
22 Note the administrative levels of DRC are province (admin 1), health zone (admin 2) and health area (admin 3).
Total cases and deaths reflect data for 2024 and 2025.



















